Form 4: Inari Medical CFO Mitch Hill Executes Stock Option and Sells Shares Under 10b5-1 Plan

Inari Medical's CFO, Mitch C. Hill, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On May 13, 2024, Mitch C. Hill, the Chief Financial Officer of Inari Medical, Inc., exercised stock options to acquire 6,000 shares of common stock at a price of $0.457 per share.
• Simultaneously, Hill sold 300 shares at a weighted average price of $44.49, 3,500 shares at a weighted average price of $45.73, and 2,200 shares at a weighted average price of $46.55.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 9, 2023.
• Following these transactions, Hill directly owns 181,294 shares of Inari Medical common stock and indirectly owns 1,600 shares through his spouse.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. No indication of unusual activity or concern.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, potentially impacting the stock price.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is common among executives to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Executive compensation packages often include stock options, and it's standard practice for executives to sell shares periodically for personal financial management.
• The use of 10b5-1 trading plans is a common and accepted practice among public company executives to manage their stock holdings in compliance with insider trading regulations.
• Comparing Hill's transactions to those of other CFOs in the medical device industry would require analyzing similar Form 4 filings for companies like Medtronic, Boston Scientific, or Abbott Laboratories.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for slight price fluctuations, but the pre-planned nature of the trades mitigates concerns.

Key Dates